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Introduction
Prevalence rates of sarcopenia, defined as age-related low 
muscle mass and muscle strength, vary between 0% and 15% in 
healthy older individuals and between 2% and 34% in geriatric 
outpatients, depending on the applied definition (1). Sarcopenia 
is associated with decreased mobility, a higher risk of falls, 
dependency in activities of daily living, morbidity and mortality 
(2-4). Although there is no consensus yet on the definition of 
sarcopenia, the majority of definitions contain a measure of 
muscle mass and/or muscle strength (5-10).
Equipment to measure muscle mass and muscle strength 
is often unavailable in clinical practice due to the related 
expenses (11). Poor physical performance has been shown to 
be associated with sarcopenia (12-14). Recently, a prediction 
model was proposed to identify sarcopenia with the use of 
demographic parameters and physical performance measures 
(15). However, such a prediction model is time consuming 
due to its inclusion of multiple physical tests and complex 
calculations. Identifying individuals who could potentially 
have sarcopenia in clinical practice would be greatly facilitated 
when an easy to use physical performance measure could be 
applied to identify individuals with sarcopenia. This could lead 
to the identification of individuals who could potentially have 
sarcopenia, who could then be referred to diagnose sarcopenia.
This study aims to assess the association between physical 
performance measures and different definitions of sarcopenia in 
a clinically relevant population of geriatric outpatients. 
Methods
Study design
This cross-sectional study consisted of 140 community-
dwelling older adults who were referred to a geriatric outpatient 
clinic of a middle-sized teaching hospital (Bronovo, The 
Hague, The Netherlands) between March 2011 and January 
2012. These older adults were referred because of mobility 
problems for a comprehensive geriatric assessment. The 
study originally consists of 299 older adults, but muscle 
mass measurements were only available in 140 older adults 
as these measurements were later added as part of clinical 
care. No exclusion criteria were applied; inclusion was based 
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on referral. The study was approved by the Medical Ethical 
Committee of the Leiden University Medical Center (Leiden, 
the Netherlands). Informed consent was waived as this study 
was based on regular care.  
 
Study population characteristics
Medical charts were used to retrieve information on age, sex 
and medical history. Medical history included information on 
the presence of: hypertension, myocardial infarction, chronic 
obstructive pulmonary disease, diabetes mellitus, rheumatoid- 
or osteoarthritis, Parkinson’s disease and malignancy. The 
presence of two or more of these diseases was defined as 
multimorbidity. Anthropometric measurements included height 
and body weight and were measured to the nearest 0.1 decimal. 
Cognitive functioning was measured by the Mini Mental State 
Examination (MMSE) resulting in a score ranging from 0 to 30 
points, higher scores indicating better cognitive function (16).
 
Physical performance measures, objective
Physical performance measures included balance tests, four-
meter walk test, timed up and go (TUG), chair stand test (CST) 
and handgrip strength (HGS). 
Balance tests were performed in three different positions 
(side-by-side, semi-tandem and tandem) according to the 
protocol of the Short Physical Performance Battery (17), 
and were performed with eyes open and with eyes closed. 
Individuals were classified as unable to maintain for ten 
seconds (0) and able to maintain for ten seconds (1). Tandem 
balance test with eyes closed was excluded from the present 
analysis as the number of individuals who were able to maintain 
in the tandem position for ten seconds was less than five 
individuals. 
Gait speed was obtained by a four-meter walk test where 
individuals were asked to walk at their usual pace (17). The best 
performance of two measurements was used and expressed in 
meters per second. 
The TUG measures the time in seconds needed to stand up 
from a sitting position without using hands, walk three meters, 
walk around a cone, walk three meters back and return to sitting 
position without using hands, as fast as possible. 
The CST measures the time in seconds needed to stand up 
five times from sitting position to a straight standing position 
and sit down again while keeping the arms crossed over the 
chest, as fast as possible (17).  
HGS was measured using a hydraulic handheld 
dynamometer (Jamar, Sammons Preston, Inc., Bolingbrook, IL, 
USA). Individuals were asked to squeeze as hard as possible 
three times with the right and left hand side alternately. 
Maximal HGS of the three trials was used for analysis (18) and 
expressed in kilograms. 
Higher gait speed and HGS implied a better physical 
performance while a higher TUG and CST time implied a lower 
physical performance. For all physical performance measures, 
all individuals who could not perform or finish the test or used 
hands to stand up from a sitting position, were given a time of 
100 seconds. 
Physical performance measures, subjective
In addition to the objective physical performance measures, 
two questions were asked: 1) Falls: “Did you fall in the past 
year?” (yes/no) and 2) Difficulty with walking: “Do you 
experience difficulty with walking?” (yes/no). 
Sarcopenia definitions
Muscle mass was measured using direct segmental multi-
frequency Bioelectrical Impedance Analysis (DSM-BIA; 
InBody 720, Biospace Co., Ltd, Seoul, Korea) (19). Five 
definitions of sarcopenia were used to examine the association 
between physical measures and sarcopenia: 1) Baumgartner 
et al. using appendicular lean mass (ALM) divided by height2 
(5); 2) Janssen et al. using relative skeletal muscle mass (SM) 
(SM divided by body mass) (6); 3) European Working Group 
on Sarcopenia in Older Persons (EWGSOP) using an algorithm 
of gait speed, HGS and skeletal muscle index (SMI; SM divided 
by height2) (7); 4) Foundation for National Institutes of Health 
(FNIH) definition one using HGS and ALM divided by body 
mass index (BMI) (8) and 5) The International Working Group 
on Sarcopenia (IWGS) using gait speed and ALM divided by 
height2 (9).  
Statistical analysis
Continuous variables were reported by mean ± standard 
deviation (SD) if data was normally distributed or median 
[interquartile range (IQR)] for skewed distributions. 
Associations between physical performance measures 
(independent variables) with definitions of sarcopenia 
(dependent variables) were analyzed with binary logistic 
regression analysis. Two models were used: the crude model 
and an adjusted model for sex and age. P-values of less than 
0.05 were considered statistically significant. 
For the statistically significant associations between physical 
performance measures and definitions of sarcopenia, sensitivity, 
specificity and the area under the curve (AUC) were calculated 
to determine the diagnostic accuracy. Sensitivity and specificity 
were defined as low <70%, moderate 70-90% and high >90%. 
AUC was defined as low <0.70, acceptable 0.70-0.80, excellent 
0.80-0.90 and outstanding >0.90. To test diagnostic accuracy, 
CST and HGS were dichotomized: CST ≥13 seconds (14, 
20), and HGS <20 kilograms for females and <30 kilograms 
for males were considered low (21). Statistical analyses were 
performed using Statistical Package for Social Sciences (SPSS 
Inc, Chicago, USA), version 22. 
Results
Table 1 shows the characteristics of the geriatric outpatients, 
with a mean age of 80.9 (7.1) years and 42% males. Table 2 
shows the applied definitions of sarcopenia and the prevalence 
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of sarcopenia. Prevalence of sarcopenia ranged from 3.6% to 
23.6%, depending on the definition. 
Table 1
Characteristics of geriatric outpatients (N=140)
N  Total 
General characteristics
Sex, male 140 59 (42.1)
Age, years, mean ± SD 140 80.9 ± 7.08
Body weight, kg, mean ± SD 140 71.9 ± 15.2
Height, cm, mean ± SD 140 167.2 ± 9.93
Health characteristics
Multimorbidity 134 55 (41.0)
MMSE, median [IQR] 140 27 [25-29]
Physical performance measures, objective 
Side-by-side eyes open, able to maintain 140 135 (96.4)
Semi-tandem eyes open, able to maintain 140 120 (85.7)
Tandem eyes open, able to maintain 140 53 (37.9)
Side-by-side eyes closed, able to maintain 138 114 (82.6)
Semi-tandem eyes closed, able to maintain 138 69 (50.0)
Tandem eyes closed, able to maintain 138 3 (2.2)
Gait speed, m/s, mean ± SD 140 0.77 ± 0.27
TUG, sec, median [IQR] 135 16.6 [12.1-26.2]
CST, sec, median [IQR] 138 15.6 [11.9-26.5]
HGS, kg, mean ± SD, males 59 33.1 ± 6.01
HGS, kg, mean ± SD, females 81 21.3 ± 5.11
Physical performance measures, subjective
History of falling last 12 months, yes 140 89 (63.6)
Difficulty walking last 12 months, yes 140 101 (72.1)
Muscle mass parameters 
ALM/height2, kg/m2, mean ± SD 140 7.16 ± 1.21
ALM/BMI, mean ± SD 140 0.80 ± 0.21
SMI, kg/m2, mean ± SD 140 9.21 ± 1.31
SM/body mass, %, mean ± SD 140 64.0 ± 8.79
All results are given in number (percentage) unless indicated otherwise. SD: standard 
deviation; MMSE: Mini Mental State Examination, score 0-30; IQR: interquartile range; 
TUG: Timed Up and Go; CST: Chair Stand Test; HGS: Handgrip Strength; ALM: 
Appendicular Lean Mass; BMI: Body Mass Index; SMI: Skeletal Muscle Index; SM: 
Skeletal Muscle.
Table 3 shows the association between physical performance 
measures and sarcopenia according to the applied definitions. 
Out of all balance tests, the ability to perform the tandem stance 
with eyes open was most often associated with a decreased 
likelihood to have sarcopenia (Baumgartner et al., EWGSOP 
and IWGS). CST was associated with sarcopenia by use of 
the EWGSOP and IWGS definitions. HGS was associated 
with sarcopenia using the definition of Baumgartner et al. and 
IWGS. The other physical performance measures i.e. semi-
tandem balance test with eyes open and eyes closed, gait speed, 
TUG and the subjective physical performance measures did not 
show an association with any of the definitions of sarcopenia. 
Table 4 shows the diagnostic accuracy for physical 
performance measures significantly associated with sarcopenia. 
The tandem balance test with eyes open showed moderate 
sensitivity and low specificity and AUC for all three sarcopenia 
definitions. The side-by-side test with eyes closed showed 
low sensitivity, moderate specificity and low AUC for the 
EWGSOP definition. CST showed low sensitivity, specificity 
and AUC for the EWGSOP and IWGS definitions. HGS 
showed low sensitivity, moderate specificity and low AUC for 
the Baumgartner et al. and IWGS definitions.  
Discussion
Physical performance measures, i.e. side-by-side test, tandem 
test, CST and HGS, were associated with sarcopenia using 
several definitions, but diagnostic accuracy was poor. 
Previous studies have shown that tandem balance test, 
gait speed, CST and HGS are valid and reliable measures to 
assess physical performance (22, 23). Moreover, gait speed, 
CST and HGS have proven to be associated with sarcopenia 
according to the EWGSOP definition in community dwelling 
older adults (20, 24, 25). Unfortunately, the results of this 
study in geriatric outpatients did not show a single suitable 
physical performance measure to identify older individuals with 
sarcopenia. For a test to be suitable to identify individuals with 
a high risk on sarcopenia, it needs to have a high sensitivity as 
especially false-negatives are undesirable. Sensitivity was low 
to moderate, which would mean that many individuals who 
could potentially have sarcopenia would be missed. Moreover, 
specificity and AUC were low and therefore single physical 
performance measures have poor diagnostic accuracy to 
identify individuals with sarcopenia. 
Sarcopenia is associated with negative health outcomes and 
therefore an important diagnosis in clinical practice. Nutritional 
and physical interventions have proven to increase muscle 
mass, muscle strength and physical performance (26, 27). 
Improving physical performance measures might reduce the 
risk of sarcopenia and therewith its negative health outcomes. 
Early recognition of sarcopenia is necessary to initiate 
interventions. BMI is a measurement that is often used to 
identify individuals who are at risk of adverse health outcomes, 
however, BMI does not encompass the risk of sarcopenia (28) 
Another proposed screening tool to identify individuals with 
sarcopenia is the SARC-F, a simple five-item questionnaire 
(subjective measures of strength, assistance in walking, rise 
from a chair, climb stairs, falls). This is one of the screening 
instruments that is increasingly being used in community-
dwelling middle-aged to older adults to identify individuals 
who could potentially have sarcopenia (29, 30).  
Multimorbidity was high in this population of geriatric 
outpatients and this could be an explanation for the lack of 
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Table 2
Prevalence of sarcopenia in geriatric outpatients according to the applied definitions of sarcopenia 
Definition Diagnostic criteria Cutoff point Prevalence, n (%) 
Males Females
Baumgartner (1998) ALM/height2 ≤7.26 kg/m2 ≤5.45 kg/m2 28 (20.0)
Janssen (2002) SM/body weight x 100% <37% <28% 24 (17.1)
EWGSOP (2010) 1. Gait speed ≤0.8 m/s ≤0.8 m/s 33 (23.6)
SMI (SM/height2) ≤10.75 kg/m2 ≤6.75 kg/m2
2. Gait speed >0.8 m/s >0.8 m/s
HGS <30 kg <20 kg
SMI (SM/height2) ≤10.75 kg/m2 ≤6.75 kg/m2
IWGS (2011) Gait speed <1.0 m/s <1.0 m/s 28 (20.0)
ALM/height2 ≤7.23 kg/m2 ≤5.67 kg/m2
FNIH (2014) HGS <26 kg <16 kg 5 (3.6)
ALM/BMI <0.789 <0.512
ALM: Appendicular Lean Mass; SM: Skeletal Muscle; EWGSOP: European Working Group on Sarcopenia in Older People; HGS: Handgrip Strength; SMI: Skeletal Muscle Index; IWGS: 
International Working Group on Sarcopenia; FNIH: Foundation for the National Institutes of Health; BMI: Body Mass Index.
Table 3
Physical performance measures and sarcopenia according to the applied definitions
Baumgartner Janssen EWGSOP IWGS FNIH
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Side-by-side, eyes open* 1.00 0.11-9.31 0.82 0.09-7.69 1.24 0.13-11.5 0.36 0.06-2.25 0.12 0.01-1.36
Adjusted model 1.47 0.15-14.4 0.60 0.06-6.46 1.32 0.10-17.5 0.58 0.09-3.85 0.05 0.00-0.82
Semi-tandem, eyes open* 1.49 0.41-5.49 0.80 0.24-2.65 0.51 0.19-1.42 1.00 0.31-3.27 0.66 0.07-6.18
Adjusted model 1.74 0.46-6.65 0.61 0.17-2.18 0.25 0.06-1.02 1.25 0.37-4.26 0.45 0.04-4.70
Tandem, eyes open* 0.29 0.10-0.82 1.83 0.75-4.44 0.44 0.18-1.07 0.29 0.10-0.82 1.10 0.18-6.80
Adjusted model 0.33 0.11-1.00 1.68 0.60-4.42 0.26 0.08-0.81 0.38 0.13-1.14 0.65 0.08-5.30
Side-by-side, eyes closed* 0.52 0.19-1.41 0.76 0.25-2.29 0.23 0.09-0.57 0.43 0.16-1.13 0.84 0.09-7.83
Adjusted model 0.58 0.21-1.65 0.66 0.21-2.10 0.07 0.01-0.33 0.51 0.18-1.40 0.66 0.07-6.58
Semi-tandem, eyes closed* 0.76 0.33-1.77 0.82 0.34-1.98 0.67 0.30-1.48 0.48 0.20-1.13 1.52 0.25-9.41
Adjusted model 0.94 0.38-2.34 0.62 0.23-1.66 0.51 0.19-1.39 0.63 0.25-1.59 1.09 0.16-7.74
Gait speed, m/s 0.41 0.08-2.07 1.54 0.30-7.83 NA NA NA NA 0.72 0.02-21.4
Adjusted model 0.44 0.08-2.46 0.79 0.14-4.48 NA NA NA NA 0.30 0.01-11.2
TUG, sec 1.01 1.00-1.02 1.00 0.99-1.01 1.00 0.99-1.02 1.01 1.00-1.02 1.01 0.99-1.04
Adjusted model 1.01 1.00-1.02 1.00 0.99-1.02 1.00 0.99-1.02 1.01 1.00-1.02 1.02 0.99-1.04
CST, sec 1.01 1.00-1.02 1.00 0.99-1.01 1.01 0.99-1.02 1.01 1.00-1.02 1.01 0.99-1.03
Adjusted model 1.01 1.00-1.02 1.00 0.99-1.08 1.02 1.00-1.03 1.01 1.00-1.02 1.02 0.99-1.04
HGS, kg 0.97 0.92-1.02 1.03 0.98-1.09 NA NA 0.96 0.91- 1.01 NA NA
Adjusted model 0.86 0.78-0.94 0.94 0.87-1.03 NA NA 0.85 0.77-0.94 NA NA
Difficulty walking, yes 0.77 0.32-1.89 2.16 0.69-6.79 1.04 0.43-2.49 1.20 0.47-3.10 1.57 0.17-14.5
Adjusted model 0.68 0.27-1.71 2.34 074-7.44 1.96 0.70-5.47 1.16 0.43-3.15 1.72 0.18-16.0
History of falling, yes 1.27 0.53-3.06 0.95 0.38-2.35 1.00 0.45-2.26 1.56 0.63-3.85 2.35 0.26-21.6
Adjusted model 1.25 0.51-3.04 0.94 0.38-2.33 1.29 0.50-3.32 1.61 0.63-4.09 2.25 0.24-21.0
OR: Odds Ratio; CI: Confidence interval; EWGSOP: European Working Group on Sarcopenia in Older People; IWGS: International Working Group on Sarcopenia; FNIH: Foundation for 
the National Institutes of Health; NA: Not Applicable; TUG: Timed Up and Go; CST: Chair Stand Test; HGS: Handgrip Strength. Adjusted model adjusted for sex and age. All results with 
a p-value < 0.05 are considered significant and are given in bold; *Balance tests were dichotomized into unable to maintain for ten seconds (0) and able to maintain for ten seconds (1).
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diagnostic accuracy of physical performance measures to 
identify older individuals with sarcopenia because physical 
performance could also be inflicted by disease-specific 
mechanisms. 
To the best of our knowledge, this is the first study outlining 
the association between various objective physical performance 
measures and several commonly used definitions of sarcopenia 
in a clinically relevant population of geriatric outpatients. 
Validated physical performance measures were used. 
Furthermore, the population is heterogeneous and no exclusion 
criteria were used which makes it a good representation of the 
actual older population visiting outpatient clinics. A limitation 
of this study could be that only BIA and not Dual Energy 
X-ray Absorptiometry (DEXA) was used to determine muscle 
mass parameters of sarcopenia. However, BIA and DEXA 
showed high agreement in a population of community-dwelling 
individuals (19). 
Single physical performance measures could not identify 
older individuals with sarcopenia, according to five different 
definitions. Therefore, no easy and fast method to identify 
individuals with sarcopenia can be recommended. Future 
research should focus on developing and validating screening 
tools so that individuals with a high probability of having 
sarcopenia can be identified. Individuals who are considered 
to be at risk of sarcopenia should be referred to diagnose 
sarcopenia using the diagnostic criteria that are used in the 
definitions of sarcopenia. 
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Table 4
Diagnostic accuracy of physical performance measures according to the applied definitions of sarcopenia
Baumgartner Janssen EWGSOP IWGS FNIH
Side-by-side, eyes open* Sensitivity NA NA NA NA 20.0
Specificity NA NA NA NA 97.0
AUC NA NA NA NA 0.59 [0.30-0.87]
Tandem, eyes open* Sensitivity 82.1 NA 75.8 82.1 NA
Specificity 42.9 NA 42.1 42.9 NA
AUC 0.63 [0.52-0.73] NA 0.59 [0.48-0.70] 0.63 [0.52-0.73] NA
Side-by-side, eyes closed* Sensitivity NA NA 36.4 NA NA
Specificity NA NA 88.6 NA NA
AUC NA NA 0.63 [0.51-0.74] NA NA
CST, dichotomized Sensitivity NA NA 81.8 85.7 NA
Specificity NA NA 34.3 34.5 NA
AUC NA NA 0.42 [0.31-0.53] 0.40 [0.29-0.51] NA
HGS, dichotomized Sensitivity 50.0 NA NA 53.6 NA
Specificity 75.0 NA NA 75.9 NA
AUC 0.63 [0.50-0.75] NA NA 0.65 [0.53-0.77] NA
Sensitivity and specificity are given in percentage; AUC is given with 95% confidence interval. EWGSOP: European Working Group on Sarcopenia in Older People; IWGS: International 
Working Group on Sarcopenia; FNIH: Foundation for the National Institutes of Health; NA: Not Applicable; AUC: Area under the curve; CST: Chair stand test; HGS: Handgrip strength. 
NA indicates non-significant results in logistic regression analyses for which no diagnostic accuracy was calculated. All results with a p-value < 0.05 are considered significant and are 
given in bold. *Balance tests were dichotomized into unable to maintain for ten seconds (0) and able to maintain for ten seconds (1). 
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